TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23676311

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 138)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (n = 152)
Number of subjects: 320
Study: 22628062

Group type: EXPERIMENTAL
Intervention: Escitalopram formulation by Grupo Tecnimede
Number of subjects: 24

Group type: COMPARATOR
Intervention: European reference formulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 20458613

Group type: EXPERIMENTAL
Intervention: New reusable skin-protective cuff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard sphygmomanometer cuff)
Number of subjects: 0
Study: 18262771

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 99

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ATP IIIA criteria
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: IDF criteria
Number of subjects: 99
Study: 16171242

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg t.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg t.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14673757

Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis
Number of subjects: 643

Group type: COMPARATOR
Intervention: No azithromycin prophylaxis
Number of subjects: 643
Study: 10227337

Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg twice daily)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 220 microg twice daily
Number of subjects: 437
Study: 8737434

Group type: EXPERIMENTAL
Intervention: Small group face‐to‐face intervention
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Formal seminar
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 1650315

Group type: EXPERIMENTAL
Intervention: Sulindac, 300 mg/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6259766

Group type: EXPERIMENTAL
Intervention: Short course of cephalothin intravenously
Number of subjects: 171

Group type: COMPARATOR
Intervention: No parenteral antibiotics
Number of subjects: 171
Study: 30616441

Group type: EXPERIMENTAL
Intervention: Stay Balanced program (progressive balance training, group sessions twice a week for 10 weeks)
Number of subjects: 15
Study: 30048979

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no metformin)
Number of subjects: 20
Study: 28359259

Group type: EXPERIMENTAL
Intervention: Sedative group (Propofol and sufentanil)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Routine group (without sedative)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 1033
Study: 26805909

Group type: EXPERIMENTAL
Intervention: RT combined with task-specific training (RTT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: RT combined with impairment-oriented training (RTI)
Number of subjects: 21
Study: 25423631

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab
Number of subjects: 29
Study: 21670709

Group type: EXPERIMENTAL
Intervention: Polyaxial locking screw plate (Group 1)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nonpolyaxial locking screw plate (Group 2)
Number of subjects: 56
Study: 18379759

Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 mg oxycodone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16521188

Group type: EXPERIMENTAL
Intervention: Topaal
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nacid
Number of subjects: 121
Study: 12969112

Group type: EXPERIMENTAL
Intervention: WarmTouch blower with CareDrape blanket
Number of subjects: 6

Group type: COMPARATOR
Intervention: BairHugger system
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ThermaCare system
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: WarmAir system
Number of subjects: 6
Study: 10634646

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDMP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G-CSF + HDMP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 8729209

Group type: EXPERIMENTAL
Intervention: Rifabutin (450 or 600 mg/d)
Number of subjects: 200
Study: 1420648

Group type: EXPERIMENTAL
Intervention: Naloxone infusion (10 mg plus 7 mg/hr for a total of 94 mg)
Number of subjects: 8
Study: 3841228

Group type: EXPERIMENTAL
Intervention: Pirenzepine 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pirenzepine 10 mg
Number of subjects: 12
Study: 31158474

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (EXER) for 16 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sedentary group receiving lifestyle counselling (CONT) for 16 weeks
Number of subjects: 96
Study: 30920880

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus fluorouracil
Number of subjects: 436

Group type: COMPARATOR
Intervention: Cisplatin plus fluorouracil
Number of subjects: 436
Study: 28250198

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention (3 education visits and specialist review of care plans)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 268
Study: 26009915

Group type: EXPERIMENTAL
Intervention: Amnion membrane (AM) + deproteinized bovine bone mineral (BBM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Collagen membrane (CM) + deproteinized bovine bone mineral (BBM)
Number of subjects: 10
Study: 22952209

Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (non-CM)
Number of subjects: 280
Study: 21358504

Group type: EXPERIMENTAL
Intervention: 1.8 g/d N-3 (omega-3 fatty acids)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 19258546

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (800 IU/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium (2.0 g/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D3
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 92
Study: 17008194

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg daily for 3 days prior to quit date, then 50 mg/day for 8 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 110
Study: 14676759

Group type: EXPERIMENTAL
Intervention: 50 mg penicillin G potassium troches (Cankercillin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 100
Study: 10708160

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 mg bolus injection)
Number of subjects: 12
Study: 9089853

Group type: EXPERIMENTAL
Intervention: Caudal epidural block with 0.6 mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine before incision (n = 28)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Caudal epidural block with 0.6 mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine after surgery (n = 23)
Number of subjects: 51
Study: 1491501

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2871079

Group type: EXPERIMENTAL
Intervention: Nobecutan-gauze dressing
Number of subjects: 145

Group type: COMPARATOR
Intervention: Op-site dressing
Number of subjects: 145
Study: 31302685

Group type: EXPERIMENTAL
Intervention: LDL-C decrease (observed in NHANES III)
Number of subjects: 4756

Group type: EXPERIMENTAL
Intervention: LDL-C decrease (observed in HKOS)
Number of subjects: 4756

Group type: EXPERIMENTAL
Intervention: Genetically predicted LDL-C decrease (Mendelian randomization analysis)
Number of subjects: 4756

Group type: EXPERIMENTAL
Intervention: Statins' LDL-C-lowering proxies
Number of subjects: 4756

Group type: COMPARATOR
Intervention: Increase in LDL-C
Number of subjects: 4756
Study: 29352812

Group type: COMPARATOR
Intervention: Standardized verbal instructions
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Standardized verbal instructions in conjunction with visual aids
Number of subjects: 85
Study: 27699485

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (seated rest)
Number of subjects: 19
Study: 24021667

Group type: EXPERIMENTAL
Intervention: Fibreoptic Endoscopic Evaluation of Swallowing
Number of subjects: 138

Group type: COMPARATOR
Intervention: Facial‐Oral Tract Therapy
Number of subjects: 138
Study: 22260946

Group type: EXPERIMENTAL
Intervention: Left ventricular assist device (LVAD) support
Number of subjects: 401
Study: 20080201

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 801

Group type: COMPARATOR
Intervention: Formoterol 12 microg twice-daily
Number of subjects: 801

Group type: COMPARATOR
Intervention: Tiotropium 18 microg od
Number of subjects: 801

Group type: COMPARATOR
Intervention: Indacaterol 75 microg
Number of subjects: 801

Group type: COMPARATOR
Intervention: Indacaterol 600 microg
Number of subjects: 801
Study: 18724190

Group type: EXPERIMENTAL
Intervention: Risk Reduction Intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison interventions
Number of subjects: 32
Study: 16793625

Group type: EXPERIMENTAL
Intervention: Delisheng injection combined with IMRT
Number of subjects: 66

Group type: COMPARATOR
Intervention: IMRT alone
Number of subjects: 66
Study: 15115135

Group type: EXPERIMENTAL
Intervention: Okavax only
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: MMR-II only
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Both vaccines concomitantly
Number of subjects: 299

Group type: COMPARATOR
Intervention: MMR-II with Okavax
Number of subjects: 299
Study: 10740401

Group type: EXPERIMENTAL
Intervention: Long chain triglycerides (20% Intralipid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium- and long-chain triglycerides (1:1 mixture, 20% Lipofundina)
Number of subjects: 12
Study: 8737324

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weight training
Number of subjects: 20
Study: 1595104

Group type: EXPERIMENTAL
Intervention: Combination of 75 mg dipyridamole and 330 mg acetylsalicylic acid three times a day
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 6142906

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg) with ethanol (60 ml vodka + 60 ml water)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Triazolam (0.5 mg) with water (100 to 200 ml)
Number of subjects: 5
Study: 31579014

Group type: EXPERIMENTAL
Intervention: MOOD (self-guided internet-based intervention)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 125
Study: 28670938

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily for four weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 60
Study: 27038034

Group type: EXPERIMENTAL
Intervention: High-dose glucocorticosteroid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose glucocorticosteroid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Another type of high-dose glucocorticosteroid treatment
Number of subjects: 0
Study: 25381721

Group type: EXPERIMENTAL
Intervention: 0.5 mg ETV once daily; 2 g RGT three times daily
Number of subjects: 1000

Group type: COMPARATOR
Intervention: 0.5 mg ETV once daily; 2 g RGT dummy agent three times daily
Number of subjects: 1000
Study: 23377592

Group type: EXPERIMENTAL
Intervention: Self-care program implemented by Community Health Practitioners (CHPs) for 6 weeks, 2 hours per week
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 290
Study: 20795444

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of metoclopramide and dexamethasone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 17511246

Group type: EXPERIMENTAL
Intervention: Non-threat group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Threat group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16040370

Group type: EXPERIMENTAL
Intervention: Single drug alcohol intervention
Number of subjects: 448
Study: 11989836

Group type: EXPERIMENTAL
Intervention: Wheat grass juice (100 cc daily for 1 month)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (matching to wheat grass juice)
Number of subjects: 23
Study: 10084293

Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine (5 mg/kg for 15 patients and 25 mg/kg for 5 patients) with intravenous iron saccharate (20 mg/HD session) for four months.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo with intravenous iron saccharate (20 mg/HD session) for four months.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine with iron supplementation.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Withdrawal of iron supplementation in both groups.
Number of subjects: 20
Study: 8846249

Group type: EXPERIMENTAL
Intervention: 0.5% timolol drops
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 37
Study: 2127377

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin spray (0.4 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sublingual nitroglycerin tablet (0.4 mg)
Number of subjects: 49
Study: 7282589

Group type: EXPERIMENTAL
Intervention: Normal diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isocaloric diet with 5% carbohydrate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Normal diet after isocaloric diet
Number of subjects: 9
Study: 30827769

Group type: EXPERIMENTAL
Intervention: High-concentration (HC) 5% sodium hypochlorite
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-concentration (LC) 1% sodium hypochlorite
Number of subjects: 100
Study: 28732483

Group type: COMPARATOR
Intervention: Self-paced walking (without dual-task)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Self-paced walking with dual-task
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fast walking
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fast walking with dual-task
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Self-paced walking
Number of subjects: 32
Study: 26372387

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r) 800/100 mg once daily
Number of subjects: 273

Group type: COMPARATOR
Intervention: Darunavir/ritonavir with two nucleoside analogues (triple therapy)
Number of subjects: 273
Study: 24231879

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Top-dose phentermine plus topiramate-extended release (15/92 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21932023

Group type: EXPERIMENTAL
Intervention: Immediate placement of OsseoSpeed implants in fresh extraction sockets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Immediate placement of OsseoSpeed implants in healed edentulous ridges
Number of subjects: 20
Study: 19053977

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 17530036

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 200 mg single dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 400 mg single dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 400 mg b.i.d. for 10 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 400 mg t.i.d. for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 400 mg b.i.d. and t.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 400 mg t.i.d.
Number of subjects: 20
Study: 11704172

Group type: EXPERIMENTAL
Intervention: ORTHO EVRA/EVRA (transdermal contraceptive system delivering norelgestromin 150 microg and ethinyl estradiol 20 microg daily)
Number of subjects: 1672
Study: 9600581

Group type: EXPERIMENTAL
Intervention: Buspirone (3 x 5 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lorazepam (3 x 1 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 7598758

Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MDD)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MDD) episode duration
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Recurrence of major depressive disorder (MDD)
Number of subjects: 362
Study: 2760359

Group type: EXPERIMENTAL
Intervention: Smallpox needle (SN)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bifurcated needle (BN)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Greer 'pen' (GP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Morrow‐Brown needle (MB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Multi‐Test (MT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Blood lancet
Number of subjects: 15
Study: 789411

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 6
Study: 31506077

Group type: EXPERIMENTAL
Intervention: 12-week dietary intervention promoting weekly consumption of 2.5 cups of cruciferous vegetables and 3.5 cups of green leafy vegetables
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One-on-one telephone counseling from a registered dietitian nutritionist
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Study program evaluation
Number of subjects: 24
Study: 28232390

Group type: EXPERIMENTAL
Intervention: 'Do not interrupt' bundled intervention (wearing a vest, strategies for diverting interruptions, clinician and patient education, reminders)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control wards (blinded to the intervention)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Poststudy survey of intervention ward nurses
Number of subjects: 227
Study: 25742287

Group type: EXPERIMENTAL
Intervention: H-HOPE intervention
Number of subjects: 182

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 182
Study: 23130655

Group type: EXPERIMENTAL
Intervention: SRP plus 1% metformin gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 50
Study: 20820795

Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 261

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 261
Study: 19168154

Group type: EXPERIMENTAL
Intervention: AFI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HRE
Number of subjects: 100

Group type: COMPARATOR
Intervention: NBI
Number of subjects: 100
Study: 16715639

Group type: EXPERIMENTAL
Intervention: Six week school skills programme
Number of subjects: 13

Group type: COMPARATOR
Intervention: Regular schooling
Number of subjects: 13
Study: 15084614

Group type: EXPERIMENTAL
Intervention: ATRA and chemotherapy (CT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: ATRA and chemotherapy (CT) for maintenance
Number of subjects: 31
Study: 11437888

Group type: EXPERIMENTAL
Intervention: Aspirin (320 mg administered three times at 4-hour intervals)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 31
Study: 9710890

Group type: EXPERIMENTAL
Intervention: Interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 0
Study: 7935224

Group type: EXPERIMENTAL
Intervention: GTN (0.1%, solved in NaCl; dose 2.8 +/- 0.5 mg/h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ISDN (0.1%, solved in NaCl; dose 4.8 +/- 0.8 mg/h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl solution, 3 ml/h)
Number of subjects: 22
Study: 3428378

Group type: EXPERIMENTAL
Intervention: Four-site intradermal (i.d.) PCEC regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eight-site intradermal (i.d.) PCEC regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-site intramuscular (i.m.) PCEC regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous regimen using suckling mouse brain (SMB) rabies vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human rabies immune globulin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equine antirabies serum (EARS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized reactions related to EARS
Number of subjects: 0
Study: 29778486

Group type: EXPERIMENTAL
Intervention: Preoperative long-course chemoradiotherapy (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative long-course radiotherapy alone (RT)
Number of subjects: 0
Study: 26867075

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for reducing hostility (12-week program)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 158
Study: 24726294

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg IV over 20 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of N-acetylcysteine (NAC) and infliximab (5 mg/kg IV as a single 2-hour administration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) or NAC with infliximab
Number of subjects: 10
Study: 22806235

Group type: EXPERIMENTAL
Intervention: Note-taking intervention group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (standard teaching)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Note-taking intervention group (first-time mothers)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (first-time mothers)
Number of subjects: 126